Clinical Trial Update: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer [Phase 2]

View source ↗

Summary

Clinical trial update for a neoadjuvant phase 2 study evaluating androgen receptor inhibition with or without SRC or MEK inhibitors in prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING